Why these two injections rarely compete directly

Patients often arrive at the clinic asking which of these two injections is better. The more useful question is: which problem does this particular knee have?

ChondroFiller and Arthrosamid work on different anatomical targets within the same joint. ChondroFiller is an injectable collagen scaffold placed at the articular cartilage surface — its job is to provide a framework for the patient's own repair cells to migrate in and rebuild damaged tissue at a focal, localised defect. Arthrosamid, by contrast, settles into the synovial lining as a permanent hydrogel cushion, reducing pain and stiffness across the joint as a whole. One is a repair strategy for a specific area of cartilage loss; the other is a symptom-management strategy for diffuse osteoarthritis throughout the joint.

Because they address structurally different problems, comparing them as though they were competing treatments for the same diagnosis is rarely the right frame. For some patients, the question genuinely is either/or — because only one pattern of damage is present. For others, a clinician may find focal cartilage damage alongside established joint-wide OA and recommend both injections in a single appointment, each doing a different job.

Weight-bearing X-rays and MRI are the diagnostic foundation that makes this distinction possible.

Which knee condition each injection is designed for

The simplest way to orient yourself is to think about the pattern of damage rather than the intensity of symptoms.

If the problem is localised

ChondroFiller is designed for a focal, contained, full-thickness cartilage defect — typically under 2 cm² — sitting within a knee that is otherwise relatively intact. The surrounding cartilage, meniscus, and joint alignment are largely in reasonable condition; what is missing is a specific patch of articular surface. Younger and more active patients tend to be the primary candidates, because the goal is biological repair: the scaffold recruits the patient's own progenitor cells and supports rebuilding of cartilage-like tissue over 6–12 months. Crucially, when widespread osteoarthritis is already present across the joint, published evidence suggests outcomes with ChondroFiller are significantly worse. It is not designed to address diffuse, joint-wide degeneration.

If the problem is diffuse

Arthrosamid is designed for established knee osteoarthritis — broadly, Kellgren–Lawrence Grade II through IV — where cartilage loss and synovial irritation are spread across the joint rather than confined to one site. The goal here is not repair but sustained symptom control: reducing pain, limiting stiffness, and delaying more invasive procedures. A single injection can provide relief lasting up to 2–3 years. Activity level matters less for candidacy than it does with ChondroFiller; Arthrosamid targets durable comfort rather than biological restoration.

Why self-screening has limits

These two profiles can overlap in the same knee — focal defects sometimes coexist with broader joint wear — and symptoms alone do not reliably distinguish them. A consultant assessment, guided by MRI characterisation of cartilage depth and an onMRI™-assisted review of joint-wide status where available, is what converts this rough decision logic into a clinical recommendation.

How each injection works inside the knee

ChondroFiller is injected as a liquid collagen preparation that gels in situ within three to five minutes of being placed at the site of cartilage damage. What forms is a porous three-dimensional scaffold — the patient's own progenitor cells migrate in from the surrounding tissue, differentiate, and begin depositing cartilage-like matrix. This process is termed acellular matrix-induced chondrogenesis: no cells are added to the injection itself; the scaffold does the recruiting. A 2025 ex vivo study confirmed this cell migration directly, recording a 2.4-fold increase in DNA content within the scaffold by day 14. Over the following six to twelve months, the scaffold is progressively resorbed and replaced by the patient's own repair tissue — meaning ChondroFiller is biodegradable by design.

Arthrosamid works through an entirely different mechanism. It is a stable hydrogel — 2.5% cross-linked polyacrylamide in 97.5% sterile water — delivered as a single outpatient injection. Rather than targeting the cartilage surface, it integrates into the synovial lining, the soft tissue layer that encloses the joint. Over roughly ten to fourteen days, synovial cells grow into the gel, forming a durable sub-synovial cushion that reduces the mechanical load transmitted through the joint and dampens inflammatory activity. It does not repair cartilage. Emerging evidence from Maulana et al. (2022) also suggests a reduction in patellofemoral bone marrow lesions following Arthrosamid injection, though this is a secondary and still-developing finding.

Both treatments are delivered as ultrasound-guided outpatient injections. Neither involves theatre admission, incisions, or general anaesthesia.

One factual distinction worth understanding before consenting to Arthrosamid: the hydrogel is non-biodegradable and is not removed in routine clinical practice once integrated. That permanence is neither a reason to proceed nor a reason to decline — but it is a meaningful difference between two products that are otherwise easy to conflate.

Evidence, recovery, and how long results last

Published data for the two treatments differ in type as much as in volume — a distinction worth understanding before drawing comparisons. Arthrosamid has the larger body of knee OA-specific evidence: a 2022 systematic review (Cole, Maulana, Whitehead, and Lee, Medical Research Archives), a 6-month prospective study (Bliddal et al., 2021), and a 12-month open-label follow-up (Bliddal et al., J Orthop Surg Res 2024) confirm meaningful reductions in pain and stiffness, with registry cohorts extending observations to 2–3 years.

ChondroFiller's evidence comes from a different angle. Across more than 19,000 treated cases since 2013, the complaint rate is approximately 0.06% with no serious adverse events recorded. In published knee studies, IKDC scores improve by approximately 30 points at 12 months — comfortably exceeding the established threshold for a clinically meaningful change — and MOCART cartilage-fill scores range between 70 and 87, indicating good structural integration. The reported 70–85% good-to-excellent symptom relief rate derives from this large real-world cohort rather than from a parallel RCT programme. No head-to-head randomised controlled trial between the two products exists; any comparison is therefore necessarily indirect.

Recovery commitment

The recovery gap between the two is clinically significant and worth factoring into any decision. Arthrosamid requires approximately 14 days of relative rest to allow the hydrogel to integrate into the synovial lining; most patients return to light activity within days of the injection. ChondroFiller involves a structured rehabilitation programme of 3–12 weeks, because the scaffold must remain protected while progenitor cells migrate in and begin depositing repair tissue. This is a necessary condition of a biological repair process, not a complication of the procedure — but patients with limited capacity for extended post-injection physiotherapy input should discuss this realistically with their consultant before proceeding.

How long results last

Arthrosamid remains within the joint permanently, though pain relief from a single injection typically lasts 2–3 years; ongoing registry follow-up is addressing longer-term questions about the permanent implant. ChondroFiller's scaffold is progressively resorbed over 12–24 months and replaced by the patient's own repair tissue, with the aim of durable structural restoration rather than a fixed-term symptom window. Structural MRI data beyond three years for ChondroFiller in the knee remain limited — a genuine evidence gap that further studies are expected to address.

When both injections are used in the same session

Some knees present with both problems at once — a focal cartilage defect sitting alongside the diffuse joint-space changes of established OA. When imaging confirms both, a specialist may recommend delivering both injections in a single outpatient appointment rather than choosing between them.

The clinical logic follows from the mechanisms described above: ChondroFiller acts at the cartilage surface; Arthrosamid integrates into the synovial lining. Because neither product duplicates the other's role, combination delivery addresses two distinct anatomical targets in one visit without redundancy.

In published combined cohorts, IKDC scores improved by approximately 30 points sustained to three years — a meaningful durability signal in patients whose joint complexity would otherwise leave one dimension of pathology untreated by a single injection alone.

This is not the default pathway. Typical combined-treatment candidates are patients whose MRI reveals a contained focal defect alongside Kellgren–Lawrence grade II–III joint-space narrowing — enough OA to warrant Arthrosamid, yet with a discrete area of cartilage loss focal enough to respond to ChondroFiller. Patients with end-stage OA or extensive cartilage loss across multiple compartments generally fall outside the indicated range for either product individually.

For those who do qualify, a single appointment addresses both problems and avoids two separate post-injection recovery windows — a practical consideration given that each treatment carries its own aftercare requirements.

Cost, access, and how to find out which option applies to you

Neither injection is currently available on the NHS, and neither is covered by the major UK private medical insurers. Both require private-pay access through a specialist who offers the treatment. NHS feasibility work for Arthrosamid is under way, which may expand access in future, but at present both routes are self-funded.

As a guide, Arthrosamid costs approximately £3,000 for a single injection; ChondroFiller ranges from approximately £3,000 to £8,000, with the figure varying according to defect complexity and whether a combined approach is recommended. Both figures are guide ranges — the treating clinic will confirm the exact cost at the point of consultation, once the relevant clinical details have been reviewed.

If you have read this far and want to take the next step, the practical question is whether your knee fits one profile, the other, or both — and that requires a consultant to review your case rather than a symptom description alone. Arriving with any existing imaging is helpful; a thorough assessment will establish what further investigation is needed.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral at its consultant-led sites in Sleaford NG34 and Grantham NG31, with on-site Open MRI available to support imaging review at the same appointment. For patients for whom geography makes it more convenient, the group's London arm (London Cartilage Clinic) offers the same treatment pathways. To arrange an assessment, visit lincolnshireknee.co.uk.